Skip to main content
GutCited

L-Glutamine per Crohn's Disease

C

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

In sintesi

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

Key Study Findings

Other
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Dose: None vs: None Outcome: Gut microbiota composition Effetto: None None

Popolazione: Crohn's disease patients

Controlled Clinical Trial
Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Dose: Washed microbiota transplantation (WMT) vs: Pre-treatment baseline Outcome: Clinical remission and multi-omics changes Effetto: None None

Popolazione: Patients with Crohn's disease

Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None vs: None Outcome: Cholesterol levels Effetto: None None

Popolazione: Mouse model

Observational Study n=262
Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in …
Dose: Phenylacetylglutamine (PAGln, measured) vs: Healthy controls (n=126) Outcome: PAGln association with CD and colitis Effetto: None None

Popolazione: New-onset treatment-naive CD (n=136) + controls

In Vitro
Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.
Dose: Beclin1 constitutive activation (genetic) vs: Wild-type mice Outcome: Cytokine production in macrophage activation Effetto: None None

Popolazione: Beclin1 variant mice + AIEC infection

Review
[Regulation of inflammatory bowel disease by amino acids].
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: IBD patients

Key Statistics

3

Studi

200

Partecipanti

Positive

C

Grado

Referenced Papers

Sheng wu gong … 2022 4 citazioni
The Cochrane database … 2018 425 citazioni
Gastroenterology clinics of … 2018 67 citazioni
Current opinion in … 2017 37 citazioni
The Cochrane database … 2016 37 citazioni
Inflammatory bowel diseases 2010 89 citazioni
The Cochrane database … 2007 192 citazioni
Current opinion in … 2005 22 citazioni
Clinical nutrition (Edinburgh, … 2004 18 citazioni
Alimentary pharmacology & … 2003 179 citazioni
Revista do Hospital … 2002 39 citazioni
Current opinion in … 2002 1 citazioni
Current opinion in … 2002
The Cochrane database … 2001 149 citazioni
Current opinion in … 2000 21 citazioni
Diseases of the … 1998 26 citazioni
Zeitschrift fur Gastroenterologie 1998 18 citazioni
Schweizerische medizinische Wochenschrift. … 1996

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
5-15 g/day
ibsdsupport:
5 g three times daily (15 g/day total)
postexercisegut:
0.25-0.9 g/kg before intense exercise
gutbarriersupport:
0.5 g/kg/day (approximately 30-40 g/day for adults)

Limite massimo: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive --
Washed microbiota transplantation (WMT) -- Positive --
None -- Positive --
Phenylacetylglutamine (PAGln, measured) -- Negative 262
Beclin1 constitutive activation (genetic) -- Positive --
None -- Mixed --
None -- Negative --
None -- Mixed --

Momento migliore per l'assunzione: Between meals or before exercise; divide doses throughout the day

Safety & Side Effects

Effetti collaterali segnalati

  • Mild gastrointestinal discomfort at high doses
  • Headache
  • Dizziness at very high doses
  • Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)

Interazioni note

  • Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
  • Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
  • Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)

Livello di assunzione massimo tollerabile: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does L-Glutamine help with Crohn's Disease?
Based on 3 studies with 200 participants, there is limited but promising evidence that L-Glutamine may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.